Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15319
UPID:
PO4F3_HUMAN
Alternative names:
Brain-specific homeobox/POU domain protein 3C
Alternative UPACC:
Q15319; O60557; Q2M3F8
Background:
POU domain, class 4, transcription factor 3, also known as Brain-specific homeobox/POU domain protein 3C, plays a pivotal role in auditory system development. It functions as a transcriptional activator by binding to octamer motifs in target gene regulatory regions, crucial for hair cell differentiation in the inner ear.
Therapeutic significance:
Linked to Deafness, autosomal dominant, 15, this protein's mutation affects gene expression, leading to non-syndromic hearing loss. Understanding its role could pave the way for innovative hearing loss therapies.